MediciNova, Inc. (MNOV) is a Healthcare stock trading at $1.32 (as of 2026-06-18), with a market capitalization of $66.94M and a trailing P/E of -5.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
MediciNova, Inc. is a biopharmaceutical company developing small-molecule therapeutics for serious diseases with unmet needs, with an emphasis on conditions addressed in the United States. Its pipeline includes MN-166 (ibudilast), MN-221 (bedoradrine), MN-001 (tipelukast), and MN-029 (denibulin), and it has collaboration arrangements with multiple pharmaceutical companies.